Hirai Keigo, Yamashita Hiroko, Tomoshige Shusuke, Mishima Yugo, Niwa Tatsuya, Ohgane Kenji, Ishii Mayumi, Kanamitsu Kayoko, Ikemi Yui, Nakagawa Shinsaku, Taguchi Hideki, Sato Shinichi, Hashimoto Yuichi, Ishikawa Minoru
Graduate School of Life Sciences, Tohoku University, 2-1-1 Katahira, Aoba-ku, Sendai, Miyagi 980-8577, Japan.
Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-032, Japan.
ACS Med Chem Lett. 2022 Feb 16;13(3):396-402. doi: 10.1021/acsmedchemlett.1c00500. eCollection 2022 Mar 10.
The onset of neurodegenerative disorders (NDs), such as Alzheimer's disease, is associated with the accumulation of aggregates of misfolded proteins. We previously showed that chemical knockdown of ND-related aggregation-prone proteins can be achieved by proteolysis targeting chimeras (PROTACs). However, hetero-bifunctional PROTACs generally show poor permeability into the central nervous system, where NDs are located. Here, we document the conversion of one of our PROTACs into hydrophobic tags (HyTs), another class of degraders bearing hydrophobic degrons. This conversion decreases the molecular weight and the number of hydrogen bond donors/acceptors. All the developed HyTs lowered the level of mutant huntingtin, an aggregation-prone protein, with potency comparable to that of the parent PROTAC. Through IAM chromatography analysis and in vivo brain penetration assay of the HyTs, we discovered a brain-permeable HyT. Our results and mechanistic analysis indicate that conversion of protein degraders into HyTs could be a useful approach to improve their drug-like properties.
神经退行性疾病(NDs),如阿尔茨海默病的发病与错误折叠蛋白聚集体的积累有关。我们之前表明,通过靶向嵌合体的蛋白酶解作用(PROTACs)可以实现与ND相关的易聚集蛋白的化学敲低。然而,异双功能PROTACs通常对位于中枢神经系统中的NDs显示出较差的渗透性。在这里,我们记录了将我们的一种PROTAC转化为疏水标签(HyTs),这是另一类带有疏水降解子的降解剂。这种转化降低了分子量以及氢键供体/受体的数量。所有开发的HyTs都降低了突变型亨廷顿蛋白(一种易聚集蛋白)的水平,其效力与亲本PROTAC相当。通过对HyTs的IAM色谱分析和体内脑渗透试验,我们发现了一种可透过血脑屏障的HyT。我们的结果和机制分析表明,将蛋白质降解剂转化为HyTs可能是改善其类药性质的一种有用方法。